Chirag Shah, MD
Retina Specialist · Boston, MANPI 1487872412
Payments from drug & device makers
Across 23 payments — averaging $22,870 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$480K
- Regeneron$38K
- Apellis Pharmaceuticals, Inc.$4K
- Genentech USA, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$136
- Alcon$130
- plus $270 from 5 others
Across 8 payments — averaging $1920.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$15K
What the payments were for
- Consulting fees$13,89796%
- Food & beverage$5374%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 2 | $479,775 |
| Regeneron | 6 | $38,384 |
| Apellis Pharmaceuticals, Inc. | 5 | $4,158 |
| Genentech USA, Inc. | 2 | $3,155 |
| Regeneron Healthcare Solutions, Inc. | 1 | $136 |
| Alcon | 1 | $130 |
| Novartis | 1 | $115 |
| Alimera Sciences, Inc. | 2 | $95 |
| Astellas Pharma US Inc | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$526,008 in reported general payments places this provider in the 90th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 285 | $11,097 |
| Bromfenac Sodium | 53 | $10,520 |
| Restasis MultidoseCyclosporine | 14 | $9,124 |
| Difluprednate | 30 | $3,259 |
| Ketorolac Tromethamine | 66 | $1,284 |
| Latanoprost | 133 | $1,125 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $832 |
| Brimonidine Tartrate | 53 | $672 |
| Timolol Maleate | 51 | $535 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 68 | $458 |
| ErythromycinErythromycin Base | 39 | $417 |
| Dorzolamide Hcl | 27 | $401 |
| Diclofenac Sodium | 28 | $323 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 20 | $305 |
| Atropine Sulfate | 11 | $235 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Boston
- Jeffrey HeierBoston$15.5M
- Andre WitkinBoston$970K
- Mohamed ElmasryBoston$25K
- Brian BalliosBoston$3K
- Ilya LeskovBoston$2K
- Siamak ShokrollahiBoston$806
- Omar AbdelalBoston$806
- Xiang WerdichBoston$686
- Tina ClearyBoston$184
- Miriam Englander Paschalis IliosBoston$170
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.